Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesOther Gross PP&E AdjustmentsShares IssuedShares Outstanding
Ratios

Keros Therapeutics (KROS) Accumulated Depreciation & Amortization (2019 - 2024)

Historic Accumulated Depreciation & Amortization for Keros Therapeutics (KROS) over the last 6 years, with Q4 2024 value amounting to $2.9 million.

  • Keros Therapeutics' Accumulated Depreciation & Amortization rose 7145.35% to $2.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.9 million, marking a year-over-year increase of 7145.35%. This contributed to the annual value of $2.9 million for FY2024, which is 7145.35% up from last year.
  • Per Keros Therapeutics' latest filing, its Accumulated Depreciation & Amortization stood at $2.9 million for Q4 2024, which was up 7145.35% from $1.7 million recorded in Q4 2023.
  • In the past 5 years, Keros Therapeutics' Accumulated Depreciation & Amortization ranged from a high of $2.9 million in Q4 2024 and a low of $721000.0 during Q4 2020
  • For the 5-year period, Keros Therapeutics' Accumulated Depreciation & Amortization averaged around $1.5 million, with its median value being $1.2 million (2022).
  • As far as peak fluctuations go, Keros Therapeutics' Accumulated Depreciation & Amortization soared by 1733.7% in 2021, and later soared by 7145.35% in 2024.
  • Quarter analysis of 5 years shows Keros Therapeutics' Accumulated Depreciation & Amortization stood at $721000.0 in 2020, then increased by 17.34% to $846000.0 in 2021, then soared by 37.47% to $1.2 million in 2022, then surged by 47.89% to $1.7 million in 2023, then skyrocketed by 71.45% to $2.9 million in 2024.
  • Its Accumulated Depreciation & Amortization stands at $2.9 million for Q4 2024, versus $1.7 million for Q4 2023 and $1.2 million for Q4 2022.